Free Trial
NASDAQ:SOPH

SOPHiA GENETICS (SOPH) Stock Price, News & Analysis

SOPHiA GENETICS logo
$3.49 -0.26 (-6.93%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$3.57 +0.08 (+2.29%)
As of 07/11/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About SOPHiA GENETICS Stock (NASDAQ:SOPH)

Key Stats

Today's Range
$3.49
$3.69
50-Day Range
$2.85
$3.75
52-Week Range
$2.58
$4.92
Volume
27,392 shs
Average Volume
59,548 shs
Market Capitalization
$232.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Moderate Buy

Company Overview

SOPHiA GENETICS Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

SOPH MarketRank™: 

SOPHiA GENETICS scored higher than 55% of companies evaluated by MarketBeat, and ranked 513th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    SOPHiA GENETICS has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    SOPHiA GENETICS has received no research coverage in the past 90 days.

  • Read more about SOPHiA GENETICS's stock forecast and price target.
  • Earnings Growth

    Earnings for SOPHiA GENETICS are expected to grow in the coming year, from ($0.96) to ($0.81) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of SOPHiA GENETICS is -3.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of SOPHiA GENETICS is -3.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    SOPHiA GENETICS has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about SOPHiA GENETICS's valuation and earnings.
  • Percentage of Shares Shorted

    0.03% of the float of SOPHiA GENETICS has been sold short.
  • Short Interest Ratio / Days to Cover

    SOPHiA GENETICS has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in SOPHiA GENETICS has recently decreased by 16.23%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    SOPHiA GENETICS does not currently pay a dividend.

  • Dividend Growth

    SOPHiA GENETICS does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.03% of the float of SOPHiA GENETICS has been sold short.
  • Short Interest Ratio / Days to Cover

    SOPHiA GENETICS has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in SOPHiA GENETICS has recently decreased by 16.23%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    SOPHiA GENETICS has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for SOPHiA GENETICS this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for SOPH on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added SOPHiA GENETICS to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, SOPHiA GENETICS insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.88% of the stock of SOPHiA GENETICS is held by insiders.

  • Percentage Held by Institutions

    Only 31.59% of the stock of SOPHiA GENETICS is held by institutions.

  • Read more about SOPHiA GENETICS's insider trading history.
Receive SOPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter.

SOPH Stock News Headlines

REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).
See More Headlines

SOPH Stock Analysis - Frequently Asked Questions

SOPHiA GENETICS's stock was trading at $3.07 at the beginning of 2025. Since then, SOPH shares have increased by 13.7% and is now trading at $3.49.

SOPHiA GENETICS SA (NASDAQ:SOPH) posted its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.05. The company had revenue of $17.78 million for the quarter, compared to analyst estimates of $16.76 million. SOPHiA GENETICS had a negative net margin of 98.51% and a negative trailing twelve-month return on equity of 63.47%.
Read the conference call transcript
.

SOPHiA GENETICS (SOPH) raised $234 million in an IPO on Friday, July 23rd 2021. The company issued 13,000,000 shares at $17.00-$19.00 per share.

Top institutional shareholders of SOPHiA GENETICS include Silverberg Bernstein Capital Management LLC (0.07%).

Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that SOPHiA GENETICS investors own include Occidental Petroleum (OXY), PayPal (PYPL), Chesapeake Energy (CHK), Cheniere Energy (LNG), Rocket Pharmaceuticals (RCKT), AbCellera Biologics (ABCL) and Farmers & Merchants Bancorp (FMAO).

Company Calendar

Last Earnings
5/06/2025
Today
7/13/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SOPH
CIK
1840706
Fax
N/A
Employees
520
Year Founded
N/A

Price Target and Rating

High Price Target
$11.00
Low Price Target
$5.00
Potential Upside/Downside
+100.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$62.49 million
Net Margins
-98.51%
Pretax Margin
-96.41%
Return on Equity
-63.47%
Return on Assets
-40.06%

Debt

Debt-to-Equity Ratio
0.16
Current Ratio
3.11
Quick Ratio
2.94

Sales & Book Value

Annual Sales
$65.17 million
Price / Sales
3.57
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.48 per share
Price / Book
2.36

Miscellaneous

Outstanding Shares
66,690,000
Free Float
63,433,000
Market Cap
$232.75 million
Optionable
Not Optionable
Beta
1.00
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:SOPH) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners